Last updated: April 25, 2026
Which suppliers provide glycopyrrolate for pharmaceutical and ingredient use?
Glycopyrrolate (also spelled glycopyrrolate in some commercial contexts) is supplied through a mix of (1) API manufacturers and (2) ingredient and excipient-grade chemical distributors. The active ingredient’s commercial availability is concentrated in specialty chemical manufacturers with cGMP drug substance capability, plus broad chemical distributors that stock catalog grades and arrange custom synthesis for specific customer requirements.
What supplier categories source glycopyrrolate?
1) API manufacturers (drug substance)
Suppliers in this category manufacture glycopyrrolate as the pharmaceutical active ingredient (API), typically under cGMP (and often supply through DMF/CEP frameworks depending on region).
2) Chemical distributors (catalog and supply chain)
These firms distribute glycopyrrolate from API sources or custom synthesize via partner networks. They often offer multiple grades (e.g., “pharmaceutical,” “USP,” or “analytical” depending on product line) and provide regulatory documentation packages tied to customer needs.
3) Contract manufacturing and custom synthesis
For niche demand, some providers synthesize glycopyrrolate under customer-specific specs (including impurity profiles, particle size targets, and packaging formats). These providers may or may not be the final API manufacturer of record, depending on documentation requirements.
Who supplies glycopyrrolate? (API and distributor landscape)
Selected API and specialty manufacturers
Below is a practical supplier set used in the market for glycopyrrolate sourcing and supply-chain coverage. (Firms listed are commonly active in controlled drug substance and specialty chemical markets.)
| Supplier type |
Supplier |
Typical role in glycopyrrolate supply |
| API manufacturer |
Ami No. 1: Apifarma (API supply coverage across branded and generics markets) |
Drug substance manufacturing and API supply |
| API manufacturer |
Gland Pharma (API platform in global CDMO/biopharma supply chains) |
API and intermediates manufacturing and supply |
| API manufacturer |
Hetero Labs / Hetero (broad API portfolio and custom synthesis programs) |
Drug substance manufacturing and sourcing |
| API manufacturer |
Lupin (API manufacturing footprint) |
API supply and contract capability |
| API manufacturer |
Viatris / former legacy generic API networks |
Market channel supply through manufacturing partners |
| Specialty chemical / API player |
TCI Chemicals |
Specialty chemical supply and distribution in some markets |
| Specialty chemical / API player |
Selleck Chemicals |
Research and reference-material supply; catalog routing into customer programs |
| Specialty chemical / API player |
Merck Millipore / Sigma-Aldrich channels |
Analytical/research grades; used where documentation supports non-GMP workflows |
How to screen glycopyrrolate suppliers for pharmaceutical-grade supply
Document and compliance checks that matter
For pharmaceutical use (commercial manufacturing or clinical supply), supplier qualification hinges on documentation and control strategy:
- Regulatory file: DMF/ASMF availability, CEP/Certificate history where applicable.
- Quality system: cGMP manufacturing status for API and batch traceability.
- Specification package: assay, impurities, water content, polymorph/crystal form control if relevant, residual solvents.
- Stability: labeled retest period and storage condition compatibility.
- Change management: notification and deviation reporting process.
Supply chain reliability
- Lead time and buffer stock for glycopyrrolate, which can have periodic market tightness due to niche demand.
- Packaging aligned to your downstream process (fiber drum vs. lined container; tamper evidence).
- Analytical method transfer readiness (HPLC methods, impurity thresholds, and validated release tests).
Commercial use constraints that affect supplier selection
Glycopyrrolate is often used in products where dose accuracy and impurity control drive acceptance. That pushes buyer requirements beyond “chemical availability” into “API-grade documentation.”
Key practical constraints buyers enforce in qualification:
- Impurity limits aligned to internal thresholds and regional pharmacopeia expectations.
- Batch consistency in particle size and polymorphic behavior when the drug product process is sensitive.
- Residual solvent controls and compliance with ICH Q3C where relevant to the synthetic route used by the vendor.
What supplier footprints typically match glycopyrrolate buyers’ needs?
If you need an API for clinical or commercial manufacturing
Prioritize suppliers that can provide:
- DMF/ASMF or equivalent regulatory support
- Full CoA, BMR summaries, impurity profiles
- Stability and packaging specs compatible with development stage
If you need glycopyrrolate for analytical method development or reference use
Catalog distributors and research-grade suppliers can be appropriate when:
- You are not building GMP batch release
- Your requirement is method suitability, not regulatory filing
If you need custom impurity profile targets
Custom synthesis and CDMO-style suppliers are best aligned when:
- You require route-specific impurity control
- Your internal impurity strategy is beyond standard catalog COAs
Key Takeaways
- Glycopyrrolate sourcing splits into API manufacturers (cGMP drug substance supply) and specialty chemical distributors (catalog and supply-chain routing).
- Supplier selection should be driven by DMF/ASMF/regulatory file support, cGMP status, and impurity/stability documentation, not just chemical catalog availability.
- For pharmaceutical manufacturing, screen for full release specifications, impurity profile alignment, and change control readiness; for method/reference use, catalog-grade suppliers can satisfy non-GMP needs.
FAQs
1) Is glycopyrrolate commonly available from multiple suppliers?
Yes. Market availability typically includes multiple API routes and distributor channels, though pharmaceutical documentation and impurity profiles vary by supplier.
2) What distinguishes an API supplier from a chemical distributor for glycopyrrolate?
An API supplier provides cGMP drug substance documentation (release testing, stability, batch records) and often supports DMF/ASMF submissions, while a chemical distributor may provide catalog grades and secondary documentation.
3) What quality documents should be requested first when qualifying glycopyrrolate suppliers?
Start with CoA, specification sheet, impurity profile, stability summary, and any regulatory file (DMF/ASMF/CEP), then align on residual solvent and packaging requirements.
4) Can reference-grade glycopyrrolate be used for pharmaceutical manufacturing?
Reference-grade material typically supports analytical work and method development. Pharmaceutical manufacturing requires API-grade cGMP supply and full batch release documentation.
5) What factors most often delay glycopyrrolate supply commitments?
Common blockers include documentation completeness (specs, impurity strategy, stability) and batch release availability aligned with your requested lead time and packaging format.
References (APA)
[1] Merck KGaA. (n.d.). Sigma-Aldrich glycopyrrolate product information. Merck.
[2] TCI Chemicals. (n.d.). Glycopyrrolate product information. TCI.
[3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMF) program guidance and database resources. FDA.
[4] International Council for Harmonisation. (2002). ICH Q3C: Impurities: Residual solvents. ICH.
